Ceapro forms research alliance with IR2Dx

This alliance sets the foundation for a clinical research project which will be conducted in Germany and in Canada under the direction of Andreas Pfutzner, who is the founder of the Institute for Clinical Research, based in Mainz, Germany.

The clinical research project will compare the oral glucose tolerance test to CeaProve. The primary endpoint will be the demonstration of the superiority of the CeaProve test meal compared to the liquid formulation currently used as a standard for a glucose tolerance test.

Regarding the business terms, the development cost will be jointly covered by Ceapro and IR2Dx. Ceapro will remain responsible for the manufacturing of the product and will receive royalties on net sales in addition to regulatory milestones. IR2Dx will have worldwide marketing rights for the hospital, clinic and physician market, exclusive except in Canada, where Ceapro has retained co-promotion rights.

Gilles Gagnon, acting president and CEO of Ceapro, said: We are very pleased with the signing of this alliance, whereby we aim to demonstrate the superiority of CeaProve by collaborating with our highly experienced partners IR2Dx and Institute for Clinical Research. Furthermore, the formation of this alliance is another step in delivering on our recently announced priority actions for value creation in line with Ceapro’s core expertise.